Buparlisib (Synonyms: 布帕尼西; BKM120; NVP-BKM120)

目录号: HY-70063 纯度: 99.82%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

溶解度

动物溶解方案

实验小贴士

Buparlisib (BKM120; NVP-BKM120) 是一种 pan-class I PI3K 抑制剂，作用于 p110α/p110β/p110δ/p110γ，IC₅₀ 分别为 52 nM/166 nM/116 nM/262 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Buparlisib Chemical Structure

CAS No. : 944396-07-0

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥715	In-stock
5 mg	￥650	In-stock
10 mg	￥920	In-stock
50 mg	￥1850	In-stock
100 mg	￥2780	In-stock
200 mg	￥4200	In-stock
500 mg	现货	询价
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Buparlisib:

Buparlisib Hydrochloride In-stock

MCE 顾客使用本产品发表的 72 篇科研文献

: Buparlisib purchased from MCE. Usage Cited in: Cancer Lett. 2019 Jan;440-441:54-63. [Abstract]; The cells are transfected with either the negative control (siNC) or BTF3 siRNA for 12 hours followed by BKM-120 or AZD-6482 treatment for 48 hours. The protein abundance is determined by an immunoblotting analysis.

: Buparlisib purchased from MCE. Usage Cited in: Brain Behav. 2018 Nov;8(11):e01123. [Abstract]; The effect of BKM120 on AKT phosphorylation is examined by Western blot.

: Buparlisib purchased from MCE. Usage Cited in: PLoS One. 2018 Jul 5;13(7):e0200014. [Abstract]; Representative immunoblots of control and NHA^RAS treated with Buparlisib for 24 h.

: Buparlisib purchased from MCE. Usage Cited in: Prostate. 2018 Feb;78(3):166-177. [Abstract]; Western blot analysis of p-AKT (Ser473) in stable cell lines (Vector-DU145 and GOLM1-DU145) treated with 200 nM, 500 nM or 1 μM BKM120.

: Buparlisib purchased from MCE. Usage Cited in: Nat Med. 2016 Jul;22(7):723-6. [Abstract]; Selective response of HER2-positive PDX DF-BM355 to the combination of BKM120/RAD001. Western blot analysis of lysates from vehicle-treated or BKM120-treated DF-BM355 in vivo.

: Buparlisib purchased from MCE. Usage Cited in: Oncogene. 2016 Jul 7;35(27):3607-12. [Abstract]; (A) Immunoblot analyses in HCC1569 cells treated with BYL719, KIN193 (MedChemexpress) or BKM120 (μM). (B, C) Immunoblot analyses in BT474 and BT474-shPTEN cells treated as indicated in (A).

Buparlisib 相关产品

•相关化合物库:

•同靶点产品:

查看 PI3K 亚型特异性产品:

查看所有亚型

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC₅₀s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.

IC₅₀ & Target^[1]

p110α

52 nM (IC₅₀)

p110α-H1047R

58 nM (IC₅₀)

p110α-E545K

99 nM (IC₅₀)

p110δ

116 nM (IC₅₀)

p110β

166 nM (IC₅₀)

p110γ

262 nM (IC₅₀)

Vps34

2.4 μM (IC₅₀)

mTOR

4.6 μM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	EC₅₀	0.055 μM Compound: 15, NVP-BKM120	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in human A2780 cells after 1 hr Inhibition of PI3K-mediated AKT Ser473 phosphorylation in human A2780 cells after 1 hr	[PMID: 24900266]
A2780	EC₅₀	0.074 μM Compound: 15, NVP-BKM120	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human A2780 cells after 1 hr Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human A2780 cells after 1 hr	[PMID: 24900266]
A2780	EC₅₀	0.52 μM Compound: 15, NVP-BKM120	Antiproliferative activity against human A2780 cells after 3 days by CellTiter-Glo assay Antiproliferative activity against human A2780 cells after 3 days by CellTiter-Glo assay	[PMID: 24900266]
A2780	GI₅₀	0.635 nM Compound: 15, NVP-BKM120	Cytotoxicity against PTEN-deficient human A2780 cells after 3 days by CellTiterGlo assay Cytotoxicity against PTEN-deficient human A2780 cells after 3 days by CellTiterGlo assay	[PMID: 24900266]
A-431	IC₅₀	1.03 μM Compound: 5a	Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	1.51 μM Compound: 5a	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	2.07 μM Compound: BKM120	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 25765909]
Bel-7402	IC₅₀	1.92 μM Compound: 5a	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Bel-7402	IC₅₀	13 μM Compound: 4; BKM120	Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay	[PMID: 31117517]
BGC-823	IC₅₀	1.43 μM Compound: 5a	Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Capan-2	IC₅₀	42 μM Compound: 4; BKM120	Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay Antiproliferative activity against human Capan2 cells after 96 hrs by MTT assay	[PMID: 31117517]
D283 Med	IC₅₀	0.279 μM Compound: BKM120	Cytotoxicity against human D283 Med cells assessed as reduction in cell viability incubated for 48 hrs by Cell TiterGlo luminescent assay Cytotoxicity against human D283 Med cells assessed as reduction in cell viability incubated for 48 hrs by Cell TiterGlo luminescent assay	[PMID: 33636537]
Daoy	IC₅₀	0.279 μM Compound: BKM120	Cytotoxicity against human Daoy cells assessed as reduction in cell viability incubated for 48 hrs by Cell TiterGlo luminescent assay Cytotoxicity against human Daoy cells assessed as reduction in cell viability incubated for 48 hrs by Cell TiterGlo luminescent assay	[PMID: 33636537]
DU-145	EC₅₀	0.073 μM Compound: 15, NVP-BKM120	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in human DU145 cells harboring LKB1 mutation after 1 hr Inhibition of PI3K-mediated AKT Ser473 phosphorylation in human DU145 cells harboring LKB1 mutation after 1 hr	[PMID: 24900266]
DU-145	IC₅₀	0.91 μM Compound: 5a	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
DU-145	IC₅₀	45 μM Compound: 4; BKM120	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay	[PMID: 31117517]
HCT-116	IC₅₀	0.48 μM Compound: BKM120	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25765909]
HCT-116	IC₅₀	1.3 μM Compound: 4; BKM120	Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 31117517]
HCT-8	IC₅₀	1.7 μM Compound: 4; BKM120	Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 31117517]
HeLa	IC₅₀	1.17 μM Compound: 5a	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HeLa	IC₅₀	4.34 μM Compound: BKM120	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25765909]
HepG2	IC₅₀	3.2 μM Compound: 4; BKM120	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 31117517]
HGC-27	IC₅₀	0.99 μM Compound: 4; BKM120	Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay Antiproliferative activity against human HGC27 cells after 96 hrs by MTT assay	[PMID: 31117517]
HL-60	IC₅₀	1.51 μM Compound: BKM120	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
HT-1080	IC₅₀	2.08 μM Compound: 5a	Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Huh-7	IC₅₀	1.51 μM Compound: 5a	Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Huh-7	IC₅₀	2 μM Compound: 4; BKM120	Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 96 hrs by MTT assay	[PMID: 31117517]
HUVEC	IC₅₀	0.886 μM Compound: NVP-BKM120; BKM	Cytotoxicity against HUVEC after 72 hrs by MTT assay Cytotoxicity against HUVEC after 72 hrs by MTT assay	[PMID: 30034607]
K562	IC₅₀	0.73 μM Compound: BKM120	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
K562	IC₅₀	1.1 μM Compound: 5a	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
K562	IC₅₀	7.9 μM Compound: 4; BKM120	Antiproliferative activity against human K562 cells after 96 hrs by MTT assay Antiproliferative activity against human K562 cells after 96 hrs by MTT assay	[PMID: 31117517]
MCF7	EC₅₀	< 0.1 μM Compound: 15, NVP-BKM120	Inhibition of PI3Kalpha E545K mutant-mediated AKT Ser473 phosphorylation in human MCF7 cells after 1 hr Inhibition of PI3Kalpha E545K mutant-mediated AKT Ser473 phosphorylation in human MCF7 cells after 1 hr	[PMID: 24900266]
MCF7	IC₅₀	0.206 μM Compound: NVP-BKM120; BKM	Antiproliferative activity against human MCF7 cells harboring PIK3CA E545K mutant after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells harboring PIK3CA E545K mutant after 72 hrs by MTT assay	[PMID: 30034607]
MCF7	IC₅₀	1 μM Compound: BKM120	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25765909]
MCF7	IC₅₀	1.5 μM Compound: 5a	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MCF7	IC₅₀	11.05 μM Compound: Buparlisib	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29107429]
MCF7	IC₅₀	5.7 μM Compound: 4; BKM120	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 31117517]
MDA-MB-231	IC₅₀	1.88 μM Compound: Buparlisib	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29107429]
MDA-MB-453	IC₅₀	0.37 μM Compound: 4; BKM120	Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-453 cells after 96 hrs by MTT assay	[PMID: 31117517]
MDA-MB-468	IC₅₀	3.97 μM Compound: BKM120	Antiproliferative activity against human MDA-MB-468 cells measured after 7 days by Celltiter-glo assay Antiproliferative activity against human MDA-MB-468 cells measured after 7 days by Celltiter-glo assay	[PMID: 33309164]
MOLT-4	IC₅₀	0.8 μM Compound: 5a	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MV4-11	IC₅₀	0.73 μM Compound: BKM120	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 36272186]
NCI-H1299	IC₅₀	3.6 μM Compound: 4; BKM120	Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells after 96 hrs by MTT assay	[PMID: 31117517]
NCI-H460	IC₅₀	3.2 μM Compound: 4; BKM120	Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 96 hrs by MTT assay	[PMID: 31117517]
NCI-N87	IC₅₀	0.66 μM Compound: 5a	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
PANC-1	IC₅₀	1.83 μM Compound: 5a	Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
PC-3	IC₅₀	5.34 μM Compound: Buparlisib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29107429]
SGC-7901	IC₅₀	1.24 μM Compound: 5a	Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SW1990	IC₅₀	1.3 μM Compound: 4; BKM120	Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay Antiproliferative activity against human SW1990 cells after 96 hrs by MTT assay	[PMID: 31117517]
T47D	IC₅₀	0.286 μM Compound: NVP-BKM120; BKM	Antiproliferative activity against human T47D cells harboring PI3KCA H1047R mutant after 72 hrs by MTT assay Antiproliferative activity against human T47D cells harboring PI3KCA H1047R mutant after 72 hrs by MTT assay	[PMID: 30034607]
T47D	IC₅₀	6.92 μM Compound: Buparlisib	Cytotoxicity against human T47D cells after 72 hrs by MTT assay Cytotoxicity against human T47D cells after 72 hrs by MTT assay	[PMID: 29107429]
THP-1	IC₅₀	12 μM Compound: 4; BKM120	Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay Antiproliferative activity against human THP1 cells after 96 hrs by MTT assay	[PMID: 31117517]
U-87MG ATCC	EC₅₀	0.13 μM Compound: 15, NVP-BKM120	Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human U87MG cells after 1 hr Inhibition of PI3K-mediated AKT Ser473 phosphorylation in PTEN-deficient human U87MG cells after 1 hr	[PMID: 24900266]
U-87MG ATCC	IC₅₀	1.64 μM Compound: BKM120	Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay	[PMID: 25765909]
U-87MG ATCC	IC₅₀	4.8 μM Compound: 4; BKM120	Antiproliferative activity against human U87 cells after 96 hrs by MTT assay Antiproliferative activity against human U87 cells after 96 hrs by MTT assay	[PMID: 31117517]
U-937	IC₅₀	0.58 μM Compound: 5a	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 27427973]

体外研究
(In Vitro)

Buparlisib (NVP-BKM120) 对 I 类 PI3K（包括最常见的 p110α 突变体）表现出 50-300 nM 的活性。此外，NVP-BKM120 对 III 类和 IV 类 PI3K 表现出较低的效力，其中分别观察到 2、5、>5 和 >25 μM 的生化活性，用于抑制 VPS34、mTOR、DNAPK 和 PI4K^[1]。Buparlisib (NVP-BKM120) 以剂量和时间依赖性方式诱导多发性骨髓瘤 (MM) 细胞凋亡。浓度≥10 μM 的 Buparlisib (NVP-BKM120) 在 24 小时后在所有测试的 MM 细胞系中诱导显着细胞凋亡（与对照组相比，P<0.05）。因此，如无特别说明，以下实验均选择 10 μM Buparlisib (NVP-BKM120) 和 24 小时治疗。Buparlisib (NVP-BKM120) 治疗会导致所有测试的 MM 细胞系出现剂量依赖性生长抑制。Buparlisib (NVP-BKM120) IC₅₀ 因测试的 MM 细胞而异。在 24 小时治疗中，ARP-1、ARK 和 MM.1R 的 IC₅₀ 在 1 至 10 μM 之间，而 MM.1S 的 IC₅₀ 为 <1 μM，U266 的 IC₅₀ 在 10 至 100 μM 之间。总之，NVP-BKM120 治疗会导致 MM 细胞生长抑制和凋亡，且呈剂量和时间依赖性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在 A2780 异种移植肿瘤中，口服 3、10、30、60 和 100 mg/kg Buparlisib (NVP-BKM120) 会导致 pAKT^Ser473 发生剂量依赖性调节。在 3 和 10 mg/kg 剂量下观察到 pAKT^Ser473 的部分抑制，在 30、60 或 100 mg/kg 剂量下观察到接近完全的抑制。pAKT 的抑制（以总 AKT 为标准）与血浆和肿瘤药物暴露量均有很好的跟踪^[1]。接受 Buparlisib (NVP-BKM120)（每天每公斤 5 μM，持续 15 天）治疗的小鼠的肿瘤负担明显小于对照小鼠，以肿瘤体积（P<0.05）和循环人类 κ 链水平（P<0.05）来衡量。此外，NVP-BKM120 治疗显著延长了荷瘤小鼠的生存期（P<0.05）^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01633060	Novartis Pharmaceuticals\|Novartis	Metastatic Breast Cancer	October 3, 2012	Phase 3
NCT01820325	Novartis Pharmaceuticals\|Novartis	Non-Small Cell Lunch Cancer	September 9, 2013	Phase 1
NCT01363232	Array Biopharma, now a wholly owned subsidiary of Pfizer\|Array BioPharma	Advanced Solid Tumors\|Selected Solid Tumors	August 2011	Phase 1
NCT02035124	SCRI Development Innovations, LLC\|Novartis	Advanced Prostate Cancer	April 2014	Phase 2
NCT01613677	Novartis Pharmaceuticals\|Novartis	Treatment for Metastatic or Locally Advanced Cervical Cancer	November 2015	Phase 2
NCT01289041	Novartis Pharmaceuticals\|Novartis	Advanced Endometrial Cancer	February 2011	Phase 2
NCT01132664	Novartis Pharmaceuticals\|Novartis	Metastatic Breast Cancer\|HER2&addition; Breast Cancer	May 2010	Phase 1\|Phase 2
NCT02154776	Novartis Pharmaceuticals\|Novartis	Advanced or Metastatic Breast Cancer	June 27, 2014	Phase 1
NCT01283503	Novartis Pharmaceuticals\|Novartis	Advanced Solid Tumor	October 2009	Phase 1
NCT01737450	Centre Leon Berard\|National Cancer Institute, France\|Fondation ARC	Head and Neck Neoplasms\|Neoplasm Metastasis\|Recurrent Disease\|Progressive Disease	January 2013	Phase 2
NCT01248494	Vanderbilt-Ingram Cancer Center	Metastatic Breast Cancer	November 2010	Phase 1
NCT01297491	Novartis Pharmaceuticals\|Novartis	Non-small Cell Lung Cancer	May 2011	Phase 2
NCT01297452	Memorial Sloan Kettering Cancer Center\|Novartis Pharmaceuticals\|Sai Life Sciences	Solid Tumors	February 15, 2011	Phase 1
NCT01572727	Novartis Pharmaceuticals\|Novartis	Breast Cancer	August 2012	Phase 2\|Phase 3
NCT01790932	Dana-Farber Cancer Institute	Breast Cancer	June 2012	Phase 2
NCT01513356	Sofia Perea, Director Clinical Trials Unit.\|Novartis\|Grupo Hospital de Madrid	Breast Cancer	October 2012	Early Phase 1
NCT04338399	Adlai Nortye Biopharma Co., Ltd.	Head and Neck Cancer	December 12, 2020	Phase 3
NCT02487823	Institut Paoli-Calmettes\|Novartis	Non Castrate Metastatic Prostate Cancer	October 2014	Phase 1
NCT01487265	SCRI Development Innovations, LLC\|Novartis	Non Small Cell Lung Cancer	March 2014	Phase 2
NCT01551030	Memorial Sloan Kettering Cancer Center\|Novartis	Metastatic Transitional Cell Carcinoma of the Urothelium	March 2012	Phase 2
NCT02340780	Canadian Cancer Trials Group\|Novartis	Chronic Lymphocytic Leukemia	April 27, 2015	Phase 2
NCT01068483	Novartis Pharmaceuticals\|Novartis	Breast Cancer\|Colon Cancer\|Ovarian Cancer\|Endometrium Cancer	November 2008	Phase 1
NCT01693614	Novartis Pharmaceuticals\|Novartis	Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma	February 28, 2013	Phase 2
NCT01816984	University of Chicago\|National Cancer Institute (NCI)	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma\|Recurrent Metastatic Squamous Neck Cancer With Occult Primary\|Recurrent Salivary Gland Cancer\|Recurrent Squamous Cell Carcinoma of the Hypopharynx\|Recurrent Squamous Cell Carcinoma of the Larynx\|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity\|Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Recurrent Squamous Cell Carcinoma of the Oropharynx\|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Recurrent Verrucous Carcinoma of the Larynx\|Recurrent Verrucous Carcinoma of the Oral Cavity\|Salivary Gland Squamous Cell Carcinoma\|Stage IV Squamous Cell Carcinoma of the Hypopharynx\|Stage IV Squamous Cell Carcinoma of the Nasopharynx\|Stage IVA Salivary Gland Cancer\|Stage IVA Squamous Cell Carcinoma of the Larynx\|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IVA Squamous Cell Carcinoma of the Oropharynx\|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Stage IVA Verrucous Carcinoma of the Larynx\|Stage IVA Verrucous Carcinoma of the Oral Cavity\|Stage IVB Salivary Gland Cancer\|Stage IVB Squamous Cell Carcinoma of the Larynx\|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IVB Squamous Cell Carcinoma of the Oropharynx\|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Stage IVB Verrucous Carcinoma of the Larynx\|Stage IVB Verrucous Carcinoma of the Oral Cavity\|Stage IVC Salivary Gland Cancer\|Stage IVC Squamous Cell Carcinoma of the Larynx\|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IVC Squamous Cell Carcinoma of the Oropharynx\|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Stage IVC Verrucous Carcinoma of the Larynx\|Stage IVC Verrucous Carcinoma of the Oral Cavity\|Tongue Cancer	May 2013	Phase 1\|Phase 2
NCT01385293	Andrew J. Armstrong, MD\|Novartis Pharmaceuticals\|Duke University	Prostate Cancer\|Metastatic (Spread to Other Areas of the Body)	August 2011	Phase 2
NCT01304602	University of Kansas Medical Center	Colorectal Cancer	February 2011	Phase 1
NCT01589861	Institut Paoli-Calmettes	Breast Cancer	December 2011	Phase 1\|Phase 2
NCT01830504	Hospices Civils de Lyon	Thyroid Cancers	April 2013	Phase 2
NCT01285466	Novartis Pharmaceuticals\|Novartis	Metastatic or Locally Advanced Solid Tumors	January 2011	Phase 1
NCT01852292	Novartis Pharmaceuticals\|Novartis	Head and Neck Squamous Cell Carcinoma	October 1, 2013	Phase 2
NCT01870726	Novartis Pharmaceuticals\|Novartis	c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM	January 9, 2014	Phase 1\|Phase 2
NCT01623349	Dana-Farber Cancer Institute\|Novartis\|AstraZeneca	Ovarian Cancer\|Breast Cancer	September 2012	Phase 1
NCT02128724	University of Oxford\|Cancer Research UK\|Novartis	Carcinoma, Non-Small-Cell Lung	April 2013	Phase 1
NCT01723800	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	July 2013	Phase 1
NCT01911325	Novartis Pharmaceuticals\|Novartis	Squamous Non-small Cell Lung Cancer	October 2013	Phase 1
NCT01339442	Washington University School of Medicine\|National Cancer Institute (NCI)	Estrogen Receptor-positive Breast Cancer\|Recurrent Breast Cancer\|Stage IV Breast Cancer	November 14, 2011	Phase 1
NCT02117817	Rutgers, The State University of New Jersey\|Rutgers Cancer Institute of New Jersey\|National Cancer Institute (NCI)	Ovarian Cancer\|Endometrial Cancer\|Recurrent Ovarian Cancer\|Recurrent Endometrial Cancer	February 2015	Phase 1
NCT02049541	Kami Maddocks, MD\|Novartis\|Ohio State University Comprehensive Cancer Center	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	July 21, 2014	Phase 1
NCT01934361	Novartis Pharmaceuticals\|Novartis	Recurrent Glioblastoma Multiforme	February 28, 2014	Phase 1
NCT01610284	Novartis Pharmaceuticals\|Novartis	Breast Cancer	August 7, 2012	Phase 3
NCT02452294	University Hospital Tuebingen\|University Hospital Dresden	Malignant Melanoma\|Metastases	July 2015	Phase 2
NCT02404844	University Hospital, Essen\|iOMEDICO AG\|Novartis Pharmaceuticals	Breast Cancer	December 2014	Phase 2
NCT01576666	Novartis Pharmaceuticals\|Novartis	Dose Escalation\|Safety\|Preliminary Efficacy\|Advanced Solid Tumors\|Metastatic Breast Cancer\|Advanced Pancreatic Adenocarcinoma\|Metastatic Colorectal Cancer\|Recurrent Glioblastoma Multiforme\|Gastric Cancer\|Gastroesophageal Junction Cancer\|Triple Negative Metastatic Breast Cancer\|Hormone Receptor Positive (ER&addition;+PR&addition;, and Her2-) Metastatic Breast Cancer	July 2012	Phase 1
NCT01527877	Yonsei University	Head Neck Cancer Squamous Cell Metastatic\|Head Neck Cancer Squamous Cell Recurrent	September 2012	Phase 2
NCT01953445	Washington University School of Medicine	Breast Neoplasms	August 2014	Phase 2
NCT01397877	ARCAGY+ GINECO GROUP	Endometrial Cancer	December 2011	Phase 2
NCT02301364	Memorial Sloan Kettering Cancer Center\|Novartis	Lymphoma\|Primary Central Nervous System Lymphoma\|Recurrent+Refractory Secondary Central Nervous System Lymphoma	November 20, 2014	Phase 2
NCT02220855	Patrick Joseph Loehrer Sr.\|Novartis Pharmaceuticals\|Indiana University	Thymoma	October 1, 2014	Phase 2
NCT01719250	Mayo Clinic\|National Cancer Institute (NCI)	Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Refractory Mantle Cell Lymphoma\|Transformed Recurrent Non-Hodgkin Lymphoma	December 2012	Early Phase 1
NCT01470209	Emory University\|Novartis Pharmaceuticals	Solid Tumors\|Lung Cancer	January 2012	Phase 1
NCT02000882	US Oncology Research\|Novartis Pharmaceuticals	Brain Metastases\|Breast Cancer\|Metastatic Breast Cancer	May 29, 2014	Phase 2
NCT02303041	Anne Chang\|Novartis Pharmaceuticals\|Stanford University	Carcinoma, Basal Cell\|Recurrent Skin Cancer\|Skin Neoplasms\|Basal Cell Nevus Syndrome	February 2015	Phase 2
NCT02194049	University of California, Davis\|Novartis	Extensive Stage Small Cell Lung Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	July 2014	Phase 1
NCT01540253	Roswell Park Cancer Institute\|Novartis	Unspecified Adult Solid Tumor, Protocol Specific	May 2012	Phase 1
NCT02756247	Memorial Sloan Kettering Cancer Center\|Janssen Scientific Affairs, LLC\|Novartis Pharmaceuticals	Lymphoma\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Diffuse Large B Cell Lymphoma	May 9, 2016	Phase 1
NCT01283048	Toni Choueiri, MD\|Beth Israel Deaconess Medical Center\|Dana-Farber Cancer Institute	Renal Cell Carcinoma	September 2011	Phase 1
NCT01155453	Novartis Pharmaceuticals\|Novartis	Advanced and Selected Solid Tumors	April 2010	Phase 1
NCT01634061	Novartis Pharmaceuticals\|Novartis	Castration-resistant Prostate Cancer	September 2012	Phase 1
NCT02058381	Novartis Pharmaceuticals\|Novartis	Pre-menopausal Breast Cancer\|PI3K Pathway Inhibition	May 6, 2014	Phase 1
NCT01971489	Roswell Park Cancer Institute	Adult Solid Neoplasm\|Recurrent Non-Small Cell Lung Carcinoma\|Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	September 2015	Phase 1
NCT01550380	University of Utah\|Novartis	Endometrial Cancer	May 2014	Phase 2
NCT01591421	Canadian Cancer Trials Group\|Pfizer	Metastatic Colorectal Cancer	September 6, 2012	Phase 1\|Phase 2
NCT01806649	Prince of Songkla University	Esophageal Cancer	July 1, 2013	Phase 2
NCT01727128	Novartis Pharmaceuticals\|Novartis	Hepatic Impairment	October 2011	Phase 1
NCT01626209	Novartis Pharmaceuticals\|Novartis	Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology	July 2012	Phase 1
NCT01833169	Novartis Pharmaceuticals\|Novartis	PI3K Pathway Activated Tumors	March 29, 2013	Phase 2
NCT02048787	Novartis Pharmaceuticals\|Novartis	Renal Impairment	March 2014	Phase 1
NCT02088684	Novartis Pharmaceuticals\|Novartis	Breast Cancer	May 19, 2014	Phase 1
NCT01501604	Massachusetts General Hospital\|Novartis Pharmaceuticals	Lung Cancer\|Breast Cancer\|Colorectal Cancer\|Cholangiocarcinoma\|Solid Tumors	January 2012	Phase 2
NCT02113878	Dana-Farber Cancer Institute\|Novartis Pharmaceuticals	Carcinoma, Squamous Cell of Head and Neck\|HPV Positive Oropharyngeal Squamous Cell Carcinoma\|Hypopharyngeal Cancer\|Early Invasive Cervical Squamous Cell Carcinoma\|Carcinoma of Larynx\|Cancer of Nasopharynx	September 29, 2014	Phase 1
NCT01629615	SOLTI Breast Cancer Research Group\|Novartis Pharmaceuticals\|Dana-Farber Cancer Institute\|Stand Up To Cancer	Breast Cancer	June 2012	Phase 2
NCT01339052	Patrick Y. Wen, MD\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Novartis Pharmaceuticals\|M.D. Anderson Cancer Center\|Memorial Sloan Kettering Cancer Center\|University of California, San Francisco\|University of California, Los Angeles\|University of Utah\|Dana-Farber Cancer Institute	Glioblastoma	September 2011	Phase 2
NCT01816594	Novartis Pharmaceuticals\|Breast International Group\|German Breast Group\|SOLTI Breast Cancer Research Group\|Novartis	HER2-positive Newly Diagnosed, Primary Breast Cancer	September 3, 2013	Phase 2
NCT01741753	Dana-Farber Cancer Institute	Prostate Cancer	November 2012	Phase 1
NCT01730248	Novartis Pharmaceuticals\|Incyte Corporation\|Novartis	Myelofibrosis	December 18, 2012	Phase 1
NCT01349660	SCRI Development Innovations, LLC\|Novartis	Glioblastoma Multiforme	December 2011	Phase 1\|Phase 2
NCT02159066	Pfizer	Melanoma	July 23, 2014	Phase 2
NCT01473901	Novartis Pharmaceuticals\|Novartis	Glioblastoma	December 30, 2011	Phase 1
NCT01923168	Novartis Pharmaceuticals\|Novartis	Breast Cancer	March 11, 2014	Phase 2
NCT01570296	National Cancer Centre, Singapore\|Novartis	Non-Small Cell Lung Cancer\|Solid Tumors	October 3, 2011	Phase 1
NCT01695473	Won Kim\|Novartis\|University of California, San Francisco	High Risk Prostate Cancer	April 23, 2013	Phase 2
NCT01571024	UNC Lineberger Comprehensive Cancer Center	Advanced Solid Tumors\|Metastatic Colorectal Cancer\|Metastatic Pancreatic Cancer	May 2012	Phase 1
NCT01468688	Novartis Pharmaceuticals\|Novartis	3rd Line GIST	April 20, 2012	Phase 1
NCT01512251	University of California, San Francisco\|Novartis	BRAF Mutant Metastatic Melanoma	June 9, 2012	Phase 1\|Phase 2
NCT02614508	Emory University\|Novartis	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	January 2016	Phase 1
NCT01396499	M.D. Anderson Cancer Center\|Novartis	Leukemia	July 2012	Phase 1

分子量

410.39

Formula

C₁₈H₂₁F₃N₆O₂

CAS 号

944396-07-0

性状

固体

颜色

White to off-white

中文名称

布帕尼西

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (243.67 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4367 mL	12.1835 mL	24.3671 mL
5 mM	0.4873 mL	2.4367 mL	4.8734 mL
10 mM	0.2437 mL	1.2184 mL	2.4367 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.09 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.09 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.09 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (6.09 mM); 澄清溶液
方案五

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.09 mM); 澄清溶液

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 2.08 mg/mL (5.07 mM); 悬浊液; 超声助溶

扫码获得
动物溶解方案

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO， PEG300/PEG400，Tween 80，均可在 MCE 网站选购。

纯度 & 产品资料

纯度： 99.90%

选择批次：

Data Sheet (657 KB) SDS (393 KB)

COA (288 KB)HNMR (192 KB)LCMS (122 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Burger MT, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011 Aug 26;2(10):774-9. [Content Brief]

[2]. Zheng Y, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity. J Mol Med (Berl). 2012 Jun;90(6):695-706. [Content Brief]

[3]. Ni J, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 Jul;22(7):723-6. [Content Brief]

[4]. Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. [Content Brief]

Cell Assay ^[1]	A2780 cells are cultured in DMEM supplemented with 10% FBS. L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 1000 cells per well, 100 uL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. Buparlisib (NVP-BKM120) supplied in DMSO (20 mM) are diluted further into DMSO (7.5 uL of 20 mM Buparlisib (NVP-BKM120) in 22.5 uL DMSO. Mix well, transfer 10 uL to 20 uL DMSO, repeat until 9 concentrations have been made). The diluted Buparlisib (NVP-BKM120) solution (2 uL), is then added to cell medium (500 uL) cell medium. Equal volumes of this solution (100 uL) are added to the cells in 96 well plates and incubated at 37ºC for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] Six- to eight-week-old female severe combined immunodeficiency (SCID) mice are used. SCID mice are subcutaneously inoculated in the right flank with 1 million ARP-1 or MM.1S cells suspended in 50 μL phosphate-buffered saline (PBS). After palpable tumor developed (tumor diameter ≥5 mm), mice are treated with intraperitoneal injection of DMSO/PBS or Buparlisib (NVP-BKM120) (5 μM per kg per day) for 15 days. Tumor sizes are measured every 5 days, and blood samples are collected at the same period. Tumor burdens are evaluated by measuring tumor size and detecting circulating human kappa chain or lambda chain. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Burger MT, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011 Aug 26;2(10):774-9. [Content Brief] [2]. Zheng Y, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity. J Mol Med (Berl). 2012 Jun;90(6):695-706. [Content Brief] [3]. Ni J, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 Jul;22(7):723-6. [Content Brief] [4]. Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. [Content Brief]

Buparlisib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4367 mL	12.1835 mL	24.3671 mL	60.9177 mL
	5 mM	0.4873 mL	2.4367 mL	4.8734 mL	12.1835 mL
	10 mM	0.2437 mL	1.2184 mL	2.4367 mL	6.0918 mL
	15 mM	0.1624 mL	0.8122 mL	1.6245 mL	4.0612 mL
	20 mM	0.1218 mL	0.6092 mL	1.2184 mL	3.0459 mL
	25 mM	0.0975 mL	0.4873 mL	0.9747 mL	2.4367 mL
	30 mM	0.0812 mL	0.4061 mL	0.8122 mL	2.0306 mL
	40 mM	0.0609 mL	0.3046 mL	0.6092 mL	1.5229 mL
	50 mM	0.0487 mL	0.2437 mL	0.4873 mL	1.2184 mL
	60 mM	0.0406 mL	0.2031 mL	0.4061 mL	1.0153 mL
	80 mM	0.0305 mL	0.1523 mL	0.3046 mL	0.7615 mL
	100 mM	0.0244 mL	0.1218 mL	0.2437 mL	0.6092 mL

Help & FAQs

做细胞实验的时候，发现用 PBS 稀释母液之后就析出了是怎么回事呢？怎么处理呢？
Buparlisib 的水溶性是不好的，所以如果您用 PBS 稀释的时候浓度比较大的话是可能会析出的，做细胞实验稀释建议您直接用培养基稀释到工作液的浓度，不建议用 PBS 稀释成中间梯度，同时用培养基稀释之后建议使用超声的方式促进溶解，确保完全澄清之后再换液加到培养板中进行培养。

Keywords:

Buparlisib944396-07-0BKM120 NVP-BKM120布帕尼西BKM 120BKM-120PI3KApoptosisPhosphoinositide 3-kinaseInhibitorinhibitorinhibit

您最近查看的产品:

Buparlisib

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Buparlisib (Synonyms: 布帕尼西; BKM120; NVP-BKM120)

Customer Review

Other Forms of Buparlisib:

Buparlisib 相关抗体

MCE 顾客使用本产品发表的 72 篇科研文献

Buparlisib 相关产品

•相关化合物库:

•同靶点产品:

查看 PI3K 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Buparlisib 相关抗体:

摩尔计算器

稀释计算器

Buparlisib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z